Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.

Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.

OBJECTIVE: Aldosterone, one of the main peptides in renin angiotensin aldosterone system (RAAS), has been suggested to mediate liver fibrosis and portal hypertension. Spironolactone, an aldosterone antagonist, has beneficial effect on hyperdynamic circulation in clinical practice. However, the mecha...

Full description

Bibliographic Details
Main Authors: Wei Luo, Ying Meng, Hong-Li Ji, Chun-Qiu Pan, Shan Huang, Chang-Hui Yu, Li-Ming Xiao, Kai Cui, Shu-Yuan Ni, Zhen-Shu Zhang, Xu Li
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3316615?pdf=render

Internet

http://europepmc.org/articles/PMC3316615?pdf=render

Similar Items